Central Retinal Artery Occlusion (CRAO)

Authors:

Abdur Rehman,

Samar Mehdi,

Junaid Kalia MD

Introduction

• Opthalmological Emergency

• Complete vision loss in one eye

• Analoguous to Acute Ischemic Stroke

Epidemiology

• Occurs in an estimated 1 in 100,000 people

• Occurs in 1.90 per 100,000 in the United States white population

• Accounts for 1 in 10,000 ophthalmologic outdoor visits

• 80% of patients have a visual acuity of 20/400 or worse

• Incidence in men is 1.47 times higher than in women

• <2% patients present with bilateral involvement

• Mean age of presentation is early 60s

Anatomy

• Central retinal artery originates from the intra-orbital part of the ophthalmic artery which is the first branch of internal carotid artery

• Arises medial to the ciliary ganglion

• Usually, the first branch of the ophthalmic artery (67%), may present as a second branch (28%)

• Follows a tortuous path inside the orbital cavity

• Enters optic sheath 18.6 mm from the distal end of the optic canal, 8.0 mm behind the posterior pole of the globe

• Penetrates lower surface of the dura matter in an oblique manner 1 cm behind the eyeball on the inferomedial side of the optic nerve

• Courses through the meninges and crosses the cranial nerve to be located in its center

• Reaches the optical papilla where it divides to give branches

• Cilioretinal artery is present in 49.5% of patients and it supplies the papillomacular bundle

Figure 1: Ophthalmic artery and its branches

Microsurgical Anatomy

• Has narrowing at the level of the dural sheath and at the level of the cribriform plate

• Distance Between the dural perforation point of the Central retinal artery and the optic disc is 8.36 mm

• The average diameter is 0.4 mm

Figure 2: Cilioretinal retinal artery

Risk Factors

• Hypertension

• Hyperlipidemia

• Smoking

• Diabetes Mellitus

• Hyperhomocysteinemia

• Family history of vascular disease

• Use of cocaine

• Polycythemia vera

• Vasculitis

• Thrombophilia

• Sickle cell anemia

• Multiple myeloma

• Systemic lupus erythematosus

• Prothrombin III mutation

• Giant Cell Arteritis

• Intravitreal Injection of VEGF Therapy

• Orbital or Head Injuries

Types of Central Retinal Artery Occlusion

1. Non-arteritic permanent CRAO

• This accounts for >2/3rd of cases of CRAO.

• Non-arteritic permanent CRAO occurs when a thrombus or embolus, as a result of atherosclerotic disease, blocks the central retinal artery.

2. Non-arteritic transient CRAO

• This accounts for 15–17% of cases of CRAO.

• According to a proposed mechanism, transient vasospasm occurs due to serotonin release from platelets on atherosclerotic plaque. This vasospasm is reversible hence this form of CRAO has the best prognosis.

3. Non-arteritic CRAO with cilioretinal sparing

• Preserved perfusion of the macula by the cilioretinal artery, which is present in 49.5% of the population, results in macular sparing.

4. Arteritic CRAO

• This accounts for 4.5-5% of cases of CRAO.

• This is caused by vasculitides, which in almost all cases is Giant Cell Arteritis.

Pathophysiology

• Most common cause: Thromboembolic
• Central retinal artery occlusion is embolism formed due to atherosclerotic plaques derived from carotid artery
• Cholesterol (74%)
• Fibrin (15.5%) and
• Calcific material (10.5%)

• Most common Artertic Process: Giant Cell Arteritis. GCA causes nodular granulomatous inflammation of medium and large sized arteries leading to the development of a fragmented internal elastic lamina and FFA in patients show occlusion of posterior ciliary artery which supply the optic nerve head and cilio-retinal arteries resulting in arteritic anterior ischemic neuropathy

• Occlusion of central retinal artery leads to hypoperfusion of retina, retinal cell damage and eventually necrosis

• Central retinal artery occlusion of about 240 minutes results in irreversible retinal damage

• Other less common sources of emboli include
• Tumor emboli from cardiac myxoma
• Fat emboli from bone fractures
• Bacterial endocarditis induced emboli and
• Septicemia induced septic emboli

• Thrombi due to atherosclerotic disease, collagen-vascular diseases, inflammatory or hypercoagulable diseases can cause central retinal artery occlusion

• Other causes of occlusion include a foreign body, migraine, spasm of the central retinal artery, or encephalitis

Clinical Presentation

Clinical Features

• Presents as a transient , painless monocular vision loss (amaurosis fugax) and an afferent pupillary defect

• May be preceded by transient visual obscurations ( migrating embolism or giant cell arteritis )

• May complain of a purplish hue to the blur

• May complain of hallucinations

• Simultaneous onset of CRAO in both eyes is rare

• Central vision may be preserved if cilioretinal artery is present

• Visual acuity may vary from loss of light perception to finger counting

Figure 3: Cherry red spot , retinal edema and vessel attenuation visible in CRAO

Ocular Evaluation in different types of CRAO

Visual Field Defects In Central retinal Artery Occlusion

• Temporal island (59%)

• Central and centrocecal scotoma (19%)

• Complete blindness (10%)

• Peripheral constriction (8%)

• Paracentral scotoma (3%)

Differential Diagnosis

• Retinal vein occlusion

• Retinal detachment

• Giant cell arteritis

• Multiple sclerosis

• Acute angle-closure glaucoma

• Papilledema

• Globe rupture

• Sickle cell anemia

• Epilepsy

Investigations

• Complete blood count and coagulation assays (PT/INR, PTT)

• ESR and CRP (more reliable) levels to rule out giant cell arteritis

• CT head without contrast to rule out intracranial hemorrhage

• Fluorescein angiography for the presence of posterior ciliary artery occlusion

• Trans esophageal echocardiography to evaluate heart lesions which can be a source of emboli

• Lipid profile(LDLs should be not more than 70s mg/dL)

• Thrombophilia evaluation by a thrombophilia screen

• Consider intravenous fluorescein angiography to confirm the diagnosis

Management

• Distinguish complete from incomplete CRAO to identify patients that might benefit from treatment

• Advise the patient to have a low-fat diet rich in fruits, vegetables, fish and lean meats for secondary prevention

Lower IOP

• Perform an emergency anterior chamber paracentesis

• Perform ocular massage using a three-mirror contact lens by compressing the gobe for 10 seconds followed by a 5 second release or over closed eyelids for 15–20 minutes

• Treat with intravenous mannitol 1.5–2 g/ Kg over 30–60 min . Contraindicated if the patient is hypersensitive, severely dehydrated, or has progressive renal disease

• Inject Intravenous acetazolamide 500 stat / 250 mg every 4 hours for 24 h . Contraindicated if the patient is hypokalemic , hyponatremic and suffers from a sulfa allergy or liver, renal disease

• Treat with timolol 0.25% ophthalmic solution 1 gtt every 12 hours . If it is not effective then increase to 0.5% 1 gtt every 12 hours

Vasodilators

• Treat with Pentoxifylline 600 mg TDS (vasodilator) if the patient is not allergic to theophylline or caffeine

• Start hyperbaric oxygen 2–2.5 atm for 90 min within 8 hours of onset

• Treat with sublingual isosorbide dinitrate 10 mg. Contraindicated if patient is hypersensitive, anemic or has a recent use of phosphodiesterase inhibitors

• Start carbogen inhalation for 10 min per hour when awake and 10 min every 4 hours at night. Continue for 48–72 hours

Reduce Retinal Edema

• Treat with a single dose of 1g intravenous methylprednisolone. Not recommended for non-arteritic permanent CRAO

Dislodge the Clot

• Use Nd YAG laser 0.8–1.1 mJ intensity focused on arterial wall behind embolus to dislodge the embolus

• Perform a pars plana vitrectomy followed by embolus removal

Embolus Thrombolysis

• Administer intra arterial continuous infusion of tPA 40–80 mg or urokinase in a dose range of 300,000 to 1 million units . Contraindicated if patient has an evidence of intracerebral hemorrhage, a suspicion of subarachnoid hemorrhage, myocardial infarction, intracranial or intraspinal surgery , serious head trauma or stroke in the last 3 months , gastrointestinal or genitourinary hemorrhage in the previous 3 weeks, a history of intracerebral hemorrhage and uncontrolled hypertension at time of treatment or a blood glucose >22.22 mmol

• Perform follow-up ophthalmic examination 1-4 weeks after the event to check for neovascularization

Factors Which Influence the Visual Outcome

Site of Occlusion Of Central Retinal Artery

• Determines the amount of residual retinal circulation

Dural sheath

• Pial and intraneural collaterals are intact and establish residual retinal circulation

Lamina cribrosa

• No collaterals present to establish retinal circulation

Causes of Occlusion

• Giant cell arteritis involves the posterior ciliary artery

• When the common trunk is occluded , both arteries are occluded which is characteristic of arteritic CRAO but rare in NA-CRAO

• The combined occlusion has a much worse visual loss than in NA-CRAO

Length of CRAO

• Central retinal artery occlusion of upto 97 min has no detectable damage

• Central retinal artery occlusion of about 240 minutes results in irreversible retinal damage

• Increased duration of ischemia results in increased duration before any improvement of function occurs after circulation is restored

Patent Cilioretinal Artery

• If it supplies the foveal region, visual acuity is almost always normal

• If its supply just reaches the foveola , there is an initial marked fall of visual acuity but it improves markedly within 2–3 weeks

• If it supplies a small peripapillary region , a small visual field is present with poor visual acuity

Conclusion

• Although an accepted evidence-based therapy for CRAO does not exist , a quick diagnosis , ruling out giant cell arteritis and management to prevent further end-organ ischaemia within 6 hours of onset of symptoms must be done pending future management guidelines

Further Reading

• Argyrios Chronopoulos, James S. Schutz, Central retinal artery occlusion—A new, provisional treatment approach, Survey of Ophthalmology, Volume 64, Issue 4, 2019

• Dumitrascu, Oana M. MD, MSc; Newman, Nancy J. MD; Biousse, Valérie MD Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!, Journal of Neuro-Ophthalmology: September 2020 - Volume 40 - Issue 3 - p 333-345 doi: 10.1097/WNO.0000000000001027

Bibliography

• Ahn SJ, Woo SJ, Park KH, Jung C, Hong JH, Han MK. Retinal and choroidal changes and visual outcome in central retinal artery occlusion: an optical coherence tomography study. Am J Ophthalmol. 2015;159(4):667-676. doi:10.1016/j.ajo.2015.01.001

• Arend O, Harris A, Martin BJ, Holin M, Wolf S. Retinal blood velocities during carbogen breathing using scanning laser ophthalmoscopy. Acta Ophthalmol. 1994;72:332–6.

• Arruga J, Sanders MD. Ophthalmologic findings in 70 patients with evidence of retinal embolism. Ophthalmology. 1982 Dec;89(12):1336-47. doi: 10.1016/s0161-6420(82)34626-6. PMID: 7162779.

• Beatty S, Eong KGA. Acute occlusion of the retinal arteries: current concepts and recent advances in diagnosis and management. Emerg Med J. 2000;17:324–9.

• Biousse V, Calvetti O, Bruce BB, Newman NJ. Thrombolysis for central retinal artery occlusion. J Neuro Ophthalmol. 2007;27:215–30.

• Bypareddy R, Sagar P, Chawla R, Temkar S. Intraocular metallic foreign body causing branch retinal vein occlusion. BMJ Case Rep. 2016;2016:bcr2016214745. Published 2016 Mar 18. doi:10.1136/bcr-2016-214745

• Chen CS, Lee AW. Management of acute central retinal artery occlusion. Nat Clin Pract Neurol. 2008;4:376–83.

• Chronopoulos A, Schutz JS. Central retinal artery occlusion-A new, provisional treatment approach. Surv Ophthalmol. 2019;64(4):443-451. doi:10.1016/j.survophthal.2019.01.011

• Cugati, S., Varma, D.D., Chen, C.S. et al. Treatment Options for Central Retinal Artery Occlusion. Curr Treat Options Neurol 15, 63–77 (2013). https://doi.org/10.1007/s11940-012-0202-9

• DAHRLING BE. The Histopathology of Early Central Retinal Artery Occlusion. Arch Ophthalmol. 1965;73(4):506–510. doi:10.1001/archopht.1965.00970030508011

• Dumitrascu, Oana M. MD, MSc; Newman, Nancy J. MD; Biousse, Valérie MD Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!, Journal of Neuro-Ophthalmology: September 2020 - Volume 40 - Issue 3 - p 333-345 doi: 10.1097/WNO.0000000000001027

• Farris W, Waymack JR. Central Retinal Artery Occlusion. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2020. PMID: 29262124.

• Haritoglou C, Wolf A, Ulbig MW. Laser embolectomy for central retinal artery occlusion. Ophthalmologe. 2010;107:465–7.

• Hausmann N. High dose steroid bolus given for occlusion of central retinal artery: author’s reply. Br Med J. 1992;304:506–7.

• HAYREH, SOHAN SINGH MD, MS, PhD, DSc, FRCS, FRCOphth*; ZIMMERMAN, M BRIDGET PhD† FUNDUS CHANGES IN CENTRAL RETINAL ARTERY OCCLUSION, Retina: March 2007 - Volume 27 - Issue 3 - p 276-289 doi: 10.1097/01.iae.0000238095.97104.9b

• Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol. 2005 Sep;140(3):376-91. doi: 10.1016/j.ajo.2005.03.038. PMID: 16138997

• Incandela L, Cesarone M, Belcaro G, et al. Treatment of vascular retinal disease with pentoxifylline: a controlled, randomized trial. Angiology. 2002;53:31–4.

• Kim HM, Park YJ, Park KH, Woo SJ (2019) Correction: Visual field defects and changes in central retinal artery occlusion. PLOS ONE 14(6): e0218363. https://doi.org/10.1371/journal.pone.0218363

• KRAPIN D. OCCLUSION OF THE CENTRAL RETINAL ARTERY IN MIGRAINE. N Engl J Med. 1964 Feb 13;270:359-60. doi: 10.1056/NEJM196402132700709. PMID: 14082265.

• Landa E, Rehany U, Rumelt S. Visual functions following recovery from non-arteritic central retinal artery occlusion. Ophthalmic Surg Laser Imag. 2004;35:103.

• Leavitt JA, Larson TA, Hodge DO, Gullerud RE. The incidence of central retinal artery occlusion in Olmsted County, Minnesota. Am J Ophthalmol. 2011;152(5):820-3.e2. doi:10.1016/j.ajo.2011.05.005

• Matias Baldoncini, Alvaro Campero, Gabriel Moran, Maximiliano Avendaño, Pablo Hinojosa-Martínez, Marcela Cimmino, Pablo Buosi, Valeria Forlizzi, Joaquín Chuang, Brian Gargurevich. Microsurgical Anatomy of the Central Retinal Artery. World Neurosurgery. ISSN 1878-8750, https://doi.org/10.1016/j.wneu.2019.06.026.

• Noble J, Weizblit N, Baerlocher M, Eng K. Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review. Br J Ophthalmol. 2008;92:588–93.

• Park SJ, Choi NK, Seo KH, Park KH, Woo SJ. Nationwide incidence of clinically diagnosed central retinal artery occlusion in Korea, 2008 to 2011. Ophthalmology. 2014;121(10):1933-1938. doi:10.1016/j.ophtha.2014.04.029

• Reynard M, Hanscom TA. Neodymium: yttrium-aluminum-garnet laser arteriotomy with embolectomy for central retinal artery occlusion. Am J Ophthalmol. 2004;137:196–8.

• Rudkin, A., Lee, A. & Chen, C. Vascular risk factors for central retinal artery occlusion. Eye 24, 678–681 (2010). https://doi.org/10.1038/eye.2009.142

• Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol. 1999 Dec;128(6):733-8. doi: 10.1016/s0002-9394(99)00359-1. Erratum in: Am J Ophthalmol i2000 Dec;130(6):908. PMID: 10612510.

• RUSSELL RW. ATHEROMATOUS RETINAL EMBOLISM. Lancet. 1963 Dec 28;2(7322):1354-6. doi: 10.1016/s0140-6736(63)90737-2. PMID: 14074518.

• Satoshi Tsutsumi, M.D., Albert L. Rhoton, Jr, M.D., Microsurgical Anatomy of the Central Retinal Artery, Neurosurgery, Volume 59, Issue 4, October 2006, Pages 870–879, https://doi.org/10.1227/01.NEU.0000232654.15306.4A

• Schmidt DP, Schulte-Mönting J, Schumacher M. Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment. Am J Neuroradiol. 2002;23:1301–7.

• Shimon Rumelt, Yosef Dorenboim, Uri Rehany. Aggressive systematic treatment for central retinal artery occlusion. American Journal of Ophthalmology. DOI:https://doi.org/10.1016/S0002-9394(99)00359-1

• SINGH S, DASS R. The central artery of the retina. I. Origin and course. Br J Ophthalmol. 1960;44(4):193-212. doi:10.1136/bjo.44.4.193

• Tadi P, Najem K, Margolin E. Amaurosis Fugax. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470528/

• Tang WM, Topping TM. Vitreous surgery for central retinal artery occlusion. Arch Ophthalmol. 2000;118:1586–7.

• Varma, D., Cugati, S., Lee, A. et al. A review of central retinal artery occlusion: clinical presentation and management. Eye 27, 688–697 (2013). https://doi.org/10.1038/eye.2013.25

• W.A. Manschot. Embolism of the Central Retinal Artery: Originating from an Endocardial Myxoma. American Journal of Ophthalmology. https://doi.org/10.1016/0002-9394(59)90746-9

AizaMD™: Revolutionizing Clinical Documentation

Discover the power of our ambient clinical documentation system, designed to transform clinical encounters into structured SOAP notes with unmatched ease. Experience exceptional value for less than $3 per day—cheaper than your daily coffee!

• Save Time: Free up over 90 minutes daily for each provider.

• Boost Revenue: Increase daily revenue by at least $1,000 per provider.

• Enhance Coding Quality: Our detailed documentation supports superior coding accuracy, ensuring optimal reimbursement.

• Maximize Engagement and Interaction: Dedicate more time to patient care and less to typing, fostering richer and more effective conversations between clinicians and patients

WebSite | AppStore | PlayStore | WebApp | Chrome Extension | Short Video Explainer

AizaMD.AI - Ambient Clinical Documentation.pdf

2011.4KB

The Future of Optimized Clinical Documentation - AizaMD.AI

Revolutionize patient care with AizaMD's AI-driven clinical note-taking system. Effortlessly generate secure notes with ICD-10 codes, saving time and ensuring efficient documentation

http://aizamd.ai/

AizaMD™: Automated Radiology Report Generation!

Discover our breakthrough Radiology AI reporting platform built on Ambient AI. It enhances productivity and minimizes fatigue. Benefit from best-in-class accuracy with our automated radiology report generation, all at market-leading pricing.

📈 Efficiency: Cut dictation times by up to 50% (Less words, More report!

🎯 Focus: Keep your eyes on the images, not the keyboard!

💸 Revenue: Boost revenue by at least 20%

📑 Clarity: Patient summary in plain English

WebSite | AppStore | PlayStore | WebApp | Chrome Extension | Short Video Explainer

Introduction to ARRG - Reimagine Radiology Report Generation.pdf

1508.6KB